2018 International Congress

Saturday, October 6, 2018

1:45pm-3:15pm

Improvement in Patient Perceived Quality of Life with DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia

C. Comella, A. Brashear, J. Jankovic, D. Truong, A. Patel, M. Evatt, N. Kapa, Y. Liu, T. Nguyen-Cleary (Chicago, IL, USA)

Clinical Trials and Therapy in Movement Disorders  ·  Hall 3FG

1:45pm-3:15pm

Improvements of tremor control and life quality of refractory essential tremor patients after MR-guided focused ultrasound thalamotomy – A Taiwan experience

H.C. Lai, K. Tsai, W.C. Chang, T. Taira, C.Y. Wei (Changhua County, Taiwan)

Clinical Trials and Therapy in Movement Disorders  ·  Hall 3FG

1:45pm-3:15pm

Impulse control disorders could be accompanied by hypomanic state under intestinal levodopa infusion

K. Kashihara, M. Kitayama (Okayama, Japan)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Incremental hourly burden of “OFF” episodes on patient quality of life and health resource use among patients with Parkinson’s disease: A Neurologist/Patient Real World Assessment in the US

K. Rajagopalan, J. Barton, J. Pike (Marlborough, MA, USA)

Education in Movement Disorders  ·  Hall 3FG

1:45pm-3:15pm

Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry

D. Johansson, A. Ericsson, A. Johansson, A. Medvedev, D. Nyholm, F. Ohlsson, M. Senek, J. Spira, I. Thomas, J. Westin, F. Bergquist (Gothenburg, Sweden)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Influence of baseline OFF-time in the efficacy response of opicapone in Parkinson’s disease patients with motor fluctuations: The BIPARK-I double-blind experience

P. Korlipara, J. Ferreira, H. Gama, A. Santos, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Inherited neuromyotonia associated with a dominant-negative KCNQ2 mutation

Y.T. Hsu, W.D. Lin, Y.W. Yang, D.C. Wu, C.H. Tsai (Taichung, Taiwan)

Genetics (Non-PD)  ·  Hall 3FG

1:45pm-3:15pm

Inhibition of HDAC4 attenuates rotenone-induced abnormal increase of α-synuclein levels and affects autophagic flux in human dopaminergic SH-SY5Y cells

L. Wang, L. Liu, T. Wang (Wuhan, China)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Insular atrophy as a marker of depression in Multiple System Atrophy: A voxel-based morphometry study

N. del Campo, N. Wolpe, O. Phillips, C. Arbus, F. Ory-Magne, M. Galitzky, C. Thalamas, C. Brefel-Courbon, A. Pavy-LeTraon, P. Péran, O. Rascol (Toulouse, France)

Neuroimaging (Non-PD)  ·  Hall 3FG

1:45pm-3:15pm

Integrated Complimentary Yoga and Ayurveda Treatment Confers Significant Benefits in PD Patients

H. Babu, U. Kumbhare, T. Raju, N. R, N. R (Bengaluru, India)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG